[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,742,741
  • Shares Outstanding, K 63,066
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -198,970 K
  • EBIT $ -192 M
  • EBITDA $ -177 M
  • 60-Month Beta 0.90
  • Price/Sales 162.23
  • Price/Cash Flow N/A
  • Price/Book 17.34

Options Overview Details

View History
  • Implied Volatility 96.13% (-5.42%)
  • Historical Volatility 181.73%
  • IV Percentile 23%
  • IV Rank 10.01%
  • IV High 302.43% on 02/17/26
  • IV Low 73.19% on 10/03/25
  • Expected Move (DTE 8) 5.44 (12.43%)
  • Put/Call Vol Ratio 0.58
  • Today's Volume 800
  • Volume Avg (30-Day) 10,424
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 198,500
  • Open Int (30-Day) 173,606
  • Expected Range 38.33 to 49.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.89
  • Number of Estimates 3
  • High Estimate $-0.78
  • Low Estimate $-1.05
  • Prior Year $-0.69
  • Growth Rate Est. (year over year) -28.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.97 +68.79%
on 06/10/26
50.47 -13.15%
on 06/25/26
+17.38 (+65.67%)
since 06/09/26
3-Month
13.21 +231.83%
on 04/10/26
50.47 -13.15%
on 06/25/26
+27.53 (+168.93%)
since 04/09/26
52-Week
8.73 +402.12%
on 03/03/26
71.50 -38.69%
on 10/28/25
+28.97 (+194.79%)
since 07/09/25

Most Recent Stories

More News
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

QURE : 43.60 (+0.25%)
uniQure Announces Pricing of Upsized $225 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

QURE : 43.60 (+0.25%)
uniQure Announces $150 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

QURE : 43.60 (+0.25%)
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026...

QURE : 43.60 (+0.25%)
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure stock looks poised to soar over the long term, but it does pose meaningful risk.

QURE : 43.60 (+0.25%)
Stocks Retreat as Fed Signals Possible Higher Interest Rates

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.99%. June...

GOOGL : 353.55 (-2.31%)
AAPL : 314.81 (+0.45%)
FDXF : 153.16 (+6.88%)
TSLA : 400.07 (+1.53%)
AMD : 556.39 (+7.53%)
CME : 237.11 (-2.45%)
SPY : 750.53 (+0.69%)
META : 611.72 (+1.43%)
ADSK : 208.05 (+0.98%)
MU : 1,020.06 (+7.51%)
ORCL : 146.26 (+4.11%)
QQQ : 722.39 (+1.54%)
Stocks Mixed Ahead of FOMC Meeting Results

The S&P 500 Index ($SPX ) (SPY ) today is down -0.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. June E-mini S&P futures (ESM26...

GOOGL : 353.55 (-2.31%)
AAPL : 314.81 (+0.45%)
ADI : 397.74 (+3.20%)
FDXF : 153.16 (+6.88%)
TSLA : 400.07 (+1.53%)
JBL : 340.85 (+4.81%)
AMD : 556.39 (+7.53%)
CME : 237.11 (-2.45%)
SPY : 750.53 (+0.69%)
META : 611.72 (+1.43%)
MU : 1,020.06 (+7.51%)
QQQ : 722.39 (+1.54%)
Stocks Supported by Chip Stock Strength and Strong US Retail Sales

The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.74%. June E-mini S&P futures (ESM26...

AMAT : 608.33 (+6.63%)
AVGO : 401.20 (+3.22%)
VZ : 42.17 (-0.66%)
REXR : 34.40 (+1.42%)
$IUXX : 29,671.70 (+1.43%)
WNC : 12.43 (+1.30%)
ASML : 1,835.25 (+3.77%)
ZNU26 : 109-070 (+0.20%)
ESU26 : 7,574.75 (+0.61%)
T : 20.88 (-1.14%)
QCOM : 194.53 (+4.27%)
JBL : 340.85 (+4.81%)
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter...

QURE : 43.60 (+0.25%)
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 43.60 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 47.31
2nd Resistance Point 45.45
1st Resistance Point 44.47
Last Price 43.60
1st Support Level 41.63
2nd Support Level 39.77
3rd Support Level 38.79

See More

52-Week High 71.50
Fibonacci 61.8% 47.52
Last Price 43.60
Fibonacci 50% 40.11
Fibonacci 38.2% 32.71
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.